Clinical Research Directory
Browse clinical research sites, groups, and studies.
Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)
Sponsor: Capital Medical University
Summary
This phase 2, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke undergoing endovascular thrombectomy.
Official title: Efficacy and Safety of Anisodine Hydrobromide in Patients With Ischemic Stroke Undergoing Endovascular Treatment
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
204
Start Date
2026-08-31
Completion Date
2027-03-31
Last Updated
2026-09-02
Healthy Volunteers
No
Conditions
Interventions
Anisodine Hydrobromide
Anisodine hydrobromide, 2 mg per dose, diluted in 0.9% sodium chloride solution and administered by intravenous infusion twice daily for a total of 14 doses.
Anisodine Hydrobromide Placebo
An equivalent volume of 0.9% sodium chloride solution, administered by intravenous infusion twice daily for a total of 14 doses.
Locations (11)
Anyang People's Hospital
Anyang, China
Xuanwu Hospital,Capital Medical University
Beijing, China
Anji County People's Hospital
Huzhou, China
Jiuquan People's Hospital
Jiuquan, China
Lishui Central Hospital
Lishui, China
Shangqiu First People's Hospitl
Shangqiu, China
Suzhou Municipal Hospital of Anhui Province
Suzhou, China
Taizhou Enze Medical Center (Group) Enze Hospital
Taizhou, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
Zhangpu County Hospital
Zhangzhou, China
Zibo Central Hospital
Zibo, China